IL319327A - Methods of administering corticosteroids - Google Patents

Methods of administering corticosteroids

Info

Publication number
IL319327A
IL319327A IL319327A IL31932725A IL319327A IL 319327 A IL319327 A IL 319327A IL 319327 A IL319327 A IL 319327A IL 31932725 A IL31932725 A IL 31932725A IL 319327 A IL319327 A IL 319327A
Authority
IL
Israel
Prior art keywords
urinary
dose
hsd
inhibitor
composition
Prior art date
Application number
IL319327A
Other languages
English (en)
Hebrew (he)
Inventor
a katz David
Original Assignee
Sparrow Pharmaceuticals Inc
a katz David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sparrow Pharmaceuticals Inc, a katz David filed Critical Sparrow Pharmaceuticals Inc
Publication of IL319327A publication Critical patent/IL319327A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL319327A 2018-11-20 2019-08-14 Methods of administering corticosteroids IL319327A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862769932P 2018-11-20 2018-11-20
PCT/US2019/046449 WO2020106337A1 (en) 2018-11-20 2019-08-14 Methods for administering corticosteroids

Publications (1)

Publication Number Publication Date
IL319327A true IL319327A (en) 2025-05-01

Family

ID=70774135

Family Applications (2)

Application Number Title Priority Date Filing Date
IL319327A IL319327A (en) 2018-11-20 2019-08-14 Methods of administering corticosteroids
IL283069A IL283069B2 (en) 2018-11-20 2019-08-14 Methods of administering corticosteroids

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL283069A IL283069B2 (en) 2018-11-20 2019-08-14 Methods of administering corticosteroids

Country Status (10)

Country Link
US (2) US12220412B2 (enExample)
EP (1) EP3883578A4 (enExample)
JP (2) JP7472122B2 (enExample)
CN (1) CN113329754A (enExample)
AU (2) AU2019384074B2 (enExample)
BR (1) BR112021009653A2 (enExample)
CA (1) CA3120339A1 (enExample)
IL (2) IL319327A (enExample)
MX (2) MX2021005801A (enExample)
WO (1) WO2020106337A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
MX2021005801A (es) 2018-11-20 2021-08-05 Sparrow Pharmaceuticals Inc Metodos para administrar corticosteroides.
MX2021007709A (es) 2018-12-27 2021-12-15 Surface Ophthalmics Inc Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular.
BR112021015481A2 (pt) * 2019-02-08 2021-12-07 Sanofi Sa Otimização biotecnológica de micro-organismos para a 1,2-desidrogenação de esteroides
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
IL316907A (en) 2022-05-16 2025-01-01 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS
WO2025072521A1 (en) * 2023-09-27 2025-04-03 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid-mediated diseases
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
GB0101447D0 (en) * 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
WO2003059267A2 (en) 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
RU2352568C9 (ru) 2002-08-09 2009-06-27 Астразенека Аб [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
WO2004089380A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
JP4499106B2 (ja) 2003-05-29 2010-07-07 メルク・シャープ・エンド・ドーム・コーポレイション １１−ベータ−水酸化ステロイド脱水素酵素−１の阻害剤としてのトリアゾール誘導体
EP1680114A4 (en) 2003-10-28 2008-09-24 Amgen Inc TRIAZOL COMPOUNDS AND RELEVANT PROCEDURES
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
JP2007514731A (ja) 2003-12-19 2007-06-07 ファイザー インコーポレイテッド 糖尿病及び肥満症の治療のための１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型（１１−β−ｈｓｄ−１）の阻害剤としてのベンゼンスルホニルアミノ−ピリジン−２−イル誘導体及び関連化合物
US7507832B2 (en) 2003-12-22 2009-03-24 Eli Lilly And Company Triazole PPAR modulators
JP2007530690A (ja) 2004-03-29 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド １１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのジアリールトリアゾール
US8415354B2 (en) * 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
WO2006013948A1 (ja) 2004-08-04 2006-02-09 Taisho Pharmaceutical Co., Ltd. トリアゾール誘導体
EP1790641A4 (en) 2004-09-16 2009-08-26 Astellas Pharma Inc DERIVATIVE OF TRIAZOLE OR SALT OF SAID DERIVATIVE
EP1812407A2 (en) 2004-11-02 2007-08-01 Pfizer, Inc. Novel compounds of substituted and unsubstituted adamantyl amides
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
WO2006080533A1 (ja) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
DE602006010546D1 (de) 2005-06-16 2009-12-31 Pfizer N-(pyridin-2-yl)sulfonamidderivate
CN101198605A (zh) 2005-06-16 2008-06-11 辉瑞大药厂 N-(吡啶-2-基)-磺酰胺衍生物
JPWO2007007688A1 (ja) 2005-07-08 2009-01-29 持田製薬株式会社 ３，５−ジアミノ−１，２，４−トリアゾール誘導体
EP1922068A4 (en) 2005-08-16 2010-08-11 Icagen Inc INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
US20090082367A1 (en) 2006-03-16 2009-03-26 Astellas Pharma Inc. Triazole derivative or a salt thereof
US20070224298A1 (en) 2006-03-23 2007-09-27 Talbott Shawn M Inhibiting 11(beta)-hsd1 with citrus flavonoids
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
SMT201700154T1 (it) 2008-07-03 2017-05-08 Astellas Pharma Inc Derivato di triazolo o suo sale
EP2243494A1 (en) * 2009-04-22 2010-10-27 OntoChem GmbH Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.
WO2011068927A2 (en) 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
UA112418C2 (uk) * 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
WO2013135769A1 (en) * 2012-03-13 2013-09-19 Abbvie Inc. Method for selecting or identifying a subject for v1b antagonist therapy
CN106659723A (zh) * 2014-07-09 2017-05-10 爱普制药有限责任公司 用于治疗神经病症的方法
MA41083A1 (fr) 2015-04-07 2018-05-31 Intercept Pharmaceuticals Inc Compositions pharmaceutiques pour thérapie combinée
US10648506B2 (en) 2016-07-07 2020-05-12 Raul Mendoza Walking rig creeper interface
WO2018117063A1 (ja) 2016-12-20 2018-06-28 アステラス製薬株式会社 焦燥性興奮治療剤
MX2021005801A (es) 2018-11-20 2021-08-05 Sparrow Pharmaceuticals Inc Metodos para administrar corticosteroides.
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
WO2023225507A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
IL316907A (en) 2022-05-16 2025-01-01 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS

Also Published As

Publication number Publication date
EP3883578A4 (en) 2022-07-27
MX2021005801A (es) 2021-08-05
JP2024098991A (ja) 2024-07-24
US20210393622A1 (en) 2021-12-23
CN113329754A (zh) 2021-08-31
CA3120339A1 (en) 2020-05-28
WO2020106337A1 (en) 2020-05-28
EP3883578A1 (en) 2021-09-29
JP2022507103A (ja) 2022-01-18
IL283069A (en) 2021-06-30
US20250205227A1 (en) 2025-06-26
US12220412B2 (en) 2025-02-11
MX2025002836A (es) 2025-04-02
JP7472122B2 (ja) 2024-04-22
AU2019384074B2 (en) 2025-04-10
AU2025203033A1 (en) 2025-05-22
AU2019384074A1 (en) 2021-06-03
BR112021009653A2 (pt) 2021-08-17
IL283069B1 (en) 2025-05-01
IL283069B2 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
IL319327A (en) Methods of administering corticosteroids
US20100076045A1 (en) Stabilized pharmaceutical sub-micron suspensions and methods of forming same
JP2017197569A5 (enExample)
Crabtree et al. Glucocorticoids and immune responses
JPWO2020106337A5 (enExample)
JP2020520889A5 (enExample)
WO2015053158A1 (ja) 電池用極板の製造装置及びその製造方法
WO2004073607A2 (en) Use of steroids to treat ocular disorders
RU2021113995A (ru) Способы введения кортикостероидов
US20090075955A1 (en) Therapeutic regimens for the treatment of immunoinflammatory disorders
US5358943A (en) Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
US20170100411A1 (en) Corticosteroid formulations for maintaining corticosteroid synovial fluid concentrations
CN113634185A (zh) 一种混合药剂配备的监控方法及装置
US11376226B2 (en) Biodegradable polymer microparticle containing steroid drug and preparation method therefor
Bissell et al. Glucocorticoids
Berlinger Use and misuse of steroids
US20250073162A1 (en) A stable injectable composition of triamcinolone acetonide
Şeker et al. Modeling the dynamics of thyroid hormones and related disorders
Deepalakshmi et al. A Comprehensive Review on Corticosteroids
Snyman Rational corticosteroid therapy: clinical
INOKUCHI et al. ITP and splenectomy
Hevers et al. Aminosäuren
Subfigure Supplementary Figure 3. Overview of all conducted experiments where mineralocorticoid receptor agonists and mineralocorticoid receptor antagonists were administered.
Starch et al. Medrol®